
Novo Nordisk’s oral diabetes drug safe and effective
pharmafile | June 12, 2019 | News story | Research and Development | GLP-1, Novo Nordisk, diabetes, pharma, samgalutide
Novo Nordisk’s oral diabetes drug semaglutide is safe for those at high risk of cardiovascular complications, according to the results of a Phase 3a trial.
The human glucagon-like peptide-1 (GLP-1) drug semgalutide is currently available as a once weekly injection for patients with type 2 diabetes.
The injectable version has been shown to reduce the risk of cardiovascular events, even among those at high risk.
The new Phase 3a trial found that the oral version of the drug was safe and superior to MSD’s sitagliptin in helping patients achieve their HbA1c targets.
The oral version of semgalutide has a safety profile consistent with the GPL-1 class of drugs as a whole.
“This is the first orally-available GLP-1 (glucagon-like peptide-1) receptor agonist and that’s a pretty big deal,” said Dr Mansoor Husain, director of the Toronto General Hospital Research Institute who led the study. “Just being able to take a pill every day makes it much more accessible.”
The results of the trial were published in the journal The Lancet Diabetes & Endocrinology.
Louis Goss
Related Content

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …





